Organogenesis
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 862
- Market Cap
- -
- Introduction
Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
ReNu Shows Promise in Phase 3 Trial for Knee Osteoarthritis
• Organogenesis Holdings reports positive interim analysis from its Phase 3 trial of ReNu for knee osteoarthritis, covering 50% of 474 planned patients.
• The Data Monitoring Committee recommended the trial proceed without modifications, confirming favorable results and a consistent safety profile for ReNu.
• The fully enrolled trial with 594 patients evaluates ReNu versus saline control via intra-articular injection, measuring knee pain reduction using the WOMAC pain scale.
• Knee osteoarthritis affects approximately 31.1 million Americans, with projections estimating a rise to 34.4 million cases by 2027.
© Copyright 2025. All Rights Reserved by MedPath